CervoMed is trading 5.34% up now at $2.96 after neflamapimod received an Innovation Passport designation under the UK’s Innovative Licensing and Access Pathway on August 4, 2026.
- The designation provides coordinated regulatory and market-access support for its dementia with Lewy bodies program.
- Investors may also be anticipating management’s August 11 fireside chat on recent clinical-development progress.
- Broader healthcare strength is supportive, but the clearest catalyst is company-specific.